Looking to sell Areteia Therapeutics stock or options?
Areteia Therapeutics is developing an oral medication aimed at treating eosinophilic asthma. Their platform concentrates on creating a drug that inhibits the maturation of eosinophils, potentially reducing inflammation and easing severe asthma symptoms. This approach could allow asthma patients to manage their condition more effectively, providing a more accessible option compared to injectable therapies.
Viking Global Investors, Solas BioVentures, Maverick Capital, Saturn Partners, Bain Capital Life Sciences, Population Health Partners, GV, Marshall Wace, ARCH Venture Partners, Sanofi, Access Biotechnology.